purchase microsoft money software rosetta stone at best buy ms office 2013 cheapest price cheapest windows xp professional buy microsoft access 2007 uk buy windows server 2008 r2 license buy office 2003 basic edition buy quicken mac 2007 purchase cyberlink powerdirector cost of autocad 2012 price apple motion cost of final cut studio best buy office 2013 home and student vmware fusion cheap buy microsoft office powerpoint 2003 software
purchase ms office 2010 product key buy microsoft project 2010 student cheap office 2007 student edition buy acronis true image coreldraw graphics suite x7 prices cheap corel paint shop pro photo x2 ultimate buy eset smart security home edition buy windows 7 full uk purchase final cut pro serial buy adobe premiere elements 7.0 adobe lightroom 2 price discount photoshop cs2 cheap adobe master collection cs6 cheap toast mac purchase act 2011

Tag Archive | "erbitux"

Strategy to conquer cancer drug resistance uncovered

Friday, September 9, 2011

0 Comments

Source: info.cancerresearchuk.org Author: staff US scientists have identified a way in which cancer cells can become resistant to the cancer drug cetuximab (Erbitux), and suggest that treatments that are already available might be able to overcome this resistance. Researchers from the Dana-Farber Cancer Institute in Boston, US, have been studying why some patients only experience short-term […]

Continue reading...

Hypersensitivity Reactions to Erbitux Caused by Tick Bites.

Friday, July 1, 2011

0 Comments

Source: Gastroenterology & Endoscopy News Hypersensitivity reactions to cetuximab (Erbitux, ImClone Systems/Bristol-Myers Squibb), a monoclonal antibody approved for use in colorectal cancer, are not caused by the drug itself but by preexisting immunoglobulin E (IgE) antibodies that may result from tick bites, researchers have found. Cetuximab, like other monoclonal antibodies, is generally associated with a […]

Continue reading...

HPV and EGFR are hottest topics in head and neck cancer

Friday, May 13, 2011

0 Comments

Source: www.medscape.com Author: Zosia Chustecka The hottest topic in head and neck cancers is the role of human papillomavirus (HPV) in the disease, although there is also a lot interest in treatment with EGRF inhibitors, especially the second-generation products, according to an expert here at the European Society for Therapeutic Radiology and Oncology 11th Biennial […]

Continue reading...

ASCO: Non-platinum regimen works in head, neck cancer

Sunday, June 6, 2010

0 Comments

Source: www.medpagetoday.com Author: Michael Smith, North American Correspondent, MedPage Today A novel non-platinum-based regimen was efficacious in recurrent or metastatic squamous cell head and neck cancer, researchers said. The combination of pemetrexed (Alimta) and bevacizumab (Avastin) yielded a response rate of 30% in a small single-arm trial, according to Athanassios Argiris, MD, of the University […]

Continue reading...

ASCO: Antibody improves head and neck cancer results

Sunday, June 6, 2010

0 Comments

Source: www.medpagetoday.com Author: Michael Smith, North American Correspondent, MedPage Today A novel antibody improved outcomes for patients with advanced and inoperable squamous cell carcinoma of the head and neck, researchers reported. Combined with radiation or chemoradiation, the substance — a fully humanized monoclonal antibody dubbed nimotuzumab — significantly outperformed either modality alone in an open-label […]

Continue reading...

Presence of rash associated with improved survival in patients receiving adjuvant Erbitux® for locally advanced head and neck cancer

Tuesday, November 17, 2009

0 Comments

Source: professional.cancerconsultants.com Author: staff A multicenter randomized trial has shown that patients with locoregionally advanced head and neck cancer receiving adjuvant Erbitux® (cetuximab) and radiotherapy who develop a rash have a better survival than patients receiving this therapy who don’t develop a rash. The details of this five-year follow-up of a Phase III randomized study […]

Continue reading...

Erbitux recognized by ASCO as a 2009 major cancer advance as first SCCHN treatment to improve survival in 30 years

Monday, November 16, 2009

0 Comments

Source: www.vwd.de Author: press release The American Society of Clinical Oncology (ASCO) has once again recognized Erbitux® (cetuximab) as one of the major clinical cancer advances of 2009. This year Erbitux was selected by ASCO for providing the first significant increase in survival for 30 years in the treatment of patients with first-line recurrent and/or […]

Continue reading...

Report highlights cancer advances

Tuesday, November 10, 2009

0 Comments

Source: www.medpagetoday.com Author: Charles Bankhead, Staff Writer, MedPage Today As the war on cancer enters its fifth decade, 51 studies stood out as examples of progress that occurred in the past year, as determined by the American Society of Clinical Oncology (ASCO) and reported in “Clinical Cancer Advances 2009.” Reflecting input from specialists throughout the […]

Continue reading...

At our throats

Thursday, October 15, 2009

0 Comments

Source: www.forbes.com Author: Matthew Herper Oncologist Maura Gillison was looking for patients with tonsil cancer for a clinical study several years ago. The first enlisted was a malpractice lawyer, followed by a doctor, then a scientist. She joked to a colleague that all she needed was a rear admiral. In walked a member of the […]

Continue reading...

Erbitux® may improve treatment of squamous cell carcinoma of the esophagus

Saturday, October 3, 2009

0 Comments

Source: professional.cancerconsultants.com Author: staff Researchers from Germany have reported that Erbitux® (cetuximab) improves response rate, time to disease progression, and overall survival of patients with metastatic squamous cell carcinoma receiving Platinol® (cisplatin) and 5-FU. The details of this study appeared in the October 2009 issue of Annals of Oncology.[1] Esophageal cancer is relatively common and […]

Continue reading...